Eledon Pharmaceuticals (ELDN) Cash & Current Investments (2013 - 2026)
Eledon Pharmaceuticals posted quarterly Cash & Current Investments of $216.0 million for Q1 2026, up 72.99% year-on-year from $124.9 million in Q1 2025, and up 62.02% on a QoQ basis from $133.3 million in Q4 2025.
Eledon Pharmaceuticals (ELDN) has 14 years of Cash & Current Investments data on file, last reported at $216.0 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Current Investments rose 72.99% year-over-year to $216.0 million; the trailing twelve-month figure through Mar 2026 stood at $216.0 million (up 72.99% YoY), and the FY2025 full-year result was $133.3 million, down 4.88% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $216.0 million, up from $133.3 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $216.0 million in Q1 2026 and bottomed at $9.2 million in Q2 2022.
- The 5-year median for Cash & Current Investments is $83.6 million (2024), against an average of $92.7 million.
- The widest annual swing landed in 2022, when Cash & Current Investments tumbled 90.22%; it then soared 1155.89% in 2023.
- A 5-year view of Cash & Current Investments shows it stood at $56.4 million in 2022, then slipped by 9.41% to $51.1 million in 2023, then soared by 174.31% to $140.2 million in 2024, then retreated by 4.88% to $133.3 million in 2025, then jumped by 62.02% to $216.0 million in 2026.
- The last three Cash & Current Investments figures came in at $216.0 million (Q1 2026), $133.3 million (Q4 2025), and $183.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.13 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Eledon Pharmaceuticals | 419.90 Mn | 203.87 Mn | - | 216.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 216.04 Mn |
| Dec 31, 2025 | 133.34 Mn |
| Sep 30, 2025 | 183.13 Mn |
| Jun 30, 2025 | 107.57 Mn |
| Mar 31, 2025 | 124.88 Mn |
| Dec 31, 2024 | 140.18 Mn |
| Sep 30, 2024 | 78.19 Mn |
| Jun 30, 2024 | 83.61 Mn |
| Mar 31, 2024 | 80.11 Mn |
| Dec 31, 2023 | 51.10 Mn |
| Sep 30, 2023 | 115.54 Mn |
| Jun 30, 2023 | 101.83 Mn |
| Mar 31, 2023 | 9.40 Mn |
| Dec 31, 2022 | 56.41 Mn |
| Sep 30, 2022 | 9.20 Mn |
| Jun 30, 2022 | 9.20 Mn |
| Mar 31, 2022 | 76.68 Mn |
| Dec 31, 2021 | 84.83 Mn |
| Sep 30, 2021 | 94.04 Mn |
| Jun 30, 2021 | 9.20 Mn |
| Mar 31, 2021 | 9.20 Mn |
| Dec 31, 2020 | 9.20 Mn |
| Sep 30, 2020 | 10.10 Mn |
| Jun 30, 2020 | 8.76 Mn |
| Mar 31, 2020 | 8.76 Mn |
| Dec 31, 2019 | 8.79 Mn |
| Sep 30, 2019 | 10.81 Mn |
| Jun 30, 2019 | 13.70 Mn |
| Mar 31, 2019 | 13.70 Mn |
| Dec 31, 2018 | 12.97 Mn |
| Sep 30, 2018 | 16.32 Mn |
| Jun 30, 2018 | 19.19 Mn |
| Mar 31, 2018 | 22.52 Mn |
| Dec 31, 2017 | 17.37 Mn |
| Sep 30, 2017 | 19.16 Mn |
| Jun 30, 2017 | 22.59 Mn |
| Mar 31, 2017 | 24.40 Mn |
| Dec 31, 2016 | 1.13 Mn |
| Sep 30, 2016 | 18.63 Mn |
| Jun 30, 2016 | 12.16 Mn |
| Mar 31, 2016 | 14.30 Mn |
| Dec 31, 2015 | 24.02 Mn |
| Sep 30, 2015 | 33.17 Mn |
| Jun 30, 2015 | 59.08 Mn |
| Mar 31, 2015 | 94.16 Mn |
| Dec 31, 2014 | 105.26 Mn |
| Sep 30, 2014 | 105.46 Mn |
| Jun 30, 2014 | 21.15 Mn |
| Mar 31, 2014 | 27.01 Mn |
| Dec 31, 2013 | 31.75 Mn |
| Sep 30, 2013 | 23.11 Mn |